发布求助
文献互助 智能选刊 最新文献

Breast Cancer Management最新文献

筛选
英文 中文
Berberine can amplify cytotoxic effect of radiotherapy by targeting cancer stem cells 黄连素可通过靶向癌症干细胞增强放射治疗的细胞毒性作用
IF 0.7
Breast Cancer Management Pub Date : 2020-06-01 DOI: 10.2217/bmt-2020-0007
Sanaa A. El-Benhawy, Heba G. El-Sheredy, H. Ghanem, A. A. Abo El-Soud
{"title":"Berberine can amplify cytotoxic effect of radiotherapy by targeting cancer stem cells","authors":"Sanaa A. El-Benhawy, Heba G. El-Sheredy, H. Ghanem, A. A. Abo El-Soud","doi":"10.2217/bmt-2020-0007","DOIUrl":"https://doi.org/10.2217/bmt-2020-0007","url":null,"abstract":"Aim: Our objective was to investigate the effect of ionizing radiation (IR) and berberine on the expression of stem cell markers OCT4 and SOX2. Materials & methods: The study involved the following groups: Group I: MCF-7 spheroids as untreated control; Group II: MCF-7 spheroids treated with IR; Group III: MCF-7 spheroids treated with berberine; and Group IV: MCF-7 spheroids treated with berberine + IR. MCF-7 spheroids’ metabolic activity and viability was determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. OCT4 and SOX2 genes expression were assayed by real time-plymerase chain reaction (RT-PCR). Results: IR and berberine treatment decreased the viability of MCF-7 spheroids and reduced OCT4 and SOX2 genes expression. Combining berberine with IR leads to a significant reduction in cell viability and OCT4 and SOX2 genes expression when compared with radiation alone treated group. Conclusion: Berberine showed to be a good candidate for further studies as a new anticancer drug in the treatment of breast cancer. Berberine has a radiosensitizing effect through targeting cancer stem cells.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2020-0007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45301422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Does post mastectomy radiotherapy reduce loco-regional recurrence rates in all clinical stages of breast cancer following a complete pathological response to neoadjuvant chemotherapy? A systematic review and meta-analysis of the literature 在对新辅助化疗有完全病理反应后，乳房切除术后放疗是否降低了癌症所有临床阶段的局部区域复发率？文献的系统综述和荟萃分析
IF 0.7
Breast Cancer Management Pub Date : 2020-04-15 DOI: 10.2217/bmt-2020-0011
Reena Shah, A. Hunter-Smith, Azel Botes, Z. Rayter
{"title":"Does post mastectomy radiotherapy reduce loco-regional recurrence rates in all clinical stages of breast cancer following a complete pathological response to neoadjuvant chemotherapy? A systematic review and meta-analysis of the literature","authors":"Reena Shah, A. Hunter-Smith, Azel Botes, Z. Rayter","doi":"10.2217/bmt-2020-0011","DOIUrl":"https://doi.org/10.2217/bmt-2020-0011","url":null,"abstract":"The role of post-mastectomy radiotherapy (PMRT) has not been qualified in contemporary cohorts that have achieved complete pathological response (pCR) following neoadjuvant chemotherapy (NAC). This systematic review evaluated loco-regional recurrence (LRR) rates following PMRT for patients with pCR or pathologically lymph node negative disease (ypN0) after NAC. We identified seven papers that described LRR in 415 patients with pCR following NAC. Pooled analysis demonstrated clear benefit of PMRT on LRR (OR: 0.2 [95% CI: 0.06–0.58; p = 0.003]) and this was most pronounced in stage III/IV disease (OR: 0.12 [95% CI: 0.04–0.44; p = 0.0012]), as well as of benefit in ypN0 disease. PMRT appears to be effective in reducing LRR following pCR or ypN0 in advanced breast cancer but requires further investigation.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2020-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2020-0011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46858985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Welcome to Volume 9 of Breast Cancer Management 欢迎来到《乳腺癌管理》第九卷
IF 0.7
Breast Cancer Management Pub Date : 2020-03-01 DOI: 10.2217/bmt-2020-0006
K. Gordon
{"title":"Welcome to Volume 9 of Breast Cancer Management","authors":"K. Gordon","doi":"10.2217/bmt-2020-0006","DOIUrl":"https://doi.org/10.2217/bmt-2020-0006","url":null,"abstract":"","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2020-0006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42680182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of circulating tumor DNA testing in breast cancer liquid biopsies: getting ready for prime time 循环肿瘤DNA检测在乳腺癌症液体活检中的作用：为黄金时段做好准备
IF 0.7
Breast Cancer Management Pub Date : 2020-03-01 DOI: 10.2217/bmt-2020-0003
K. M. Koo, P. Mainwaring
{"title":"The role of circulating tumor DNA testing in breast cancer liquid biopsies: getting ready for prime time","authors":"K. M. Koo, P. Mainwaring","doi":"10.2217/bmt-2020-0003","DOIUrl":"https://doi.org/10.2217/bmt-2020-0003","url":null,"abstract":"","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2020-0003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48555086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Patient barriers to participation in breast cancer clinical trials 患者参与乳腺癌临床试验的障碍
IF 0.7
Breast Cancer Management Pub Date : 2020-03-01 DOI: 10.2217/bmt-2020-0004
P. Spears
{"title":"Patient barriers to participation in breast cancer clinical trials","authors":"P. Spears","doi":"10.2217/bmt-2020-0004","DOIUrl":"https://doi.org/10.2217/bmt-2020-0004","url":null,"abstract":"","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2020-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44967544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Direct medical costs for stage-specific breast cancer: a retrospective analysis 分期乳腺癌的直接医疗费用:回顾性分析
IF 0.7
Breast Cancer Management Pub Date : 2020-03-01 DOI: 10.2217/bmt-2019-0014
Q. Alefan, A. Saadeh, R. Yaghan
{"title":"Direct medical costs for stage-specific breast cancer: a retrospective analysis","authors":"Q. Alefan, A. Saadeh, R. Yaghan","doi":"10.2217/bmt-2019-0014","DOIUrl":"https://doi.org/10.2217/bmt-2019-0014","url":null,"abstract":"Aim: To analyze the direct medical costs of breast cancer (BC) patients in the north of Jordan. Patients: A cohort of BC patients treated during 2015 at King Abdullah University Hospital. Methods: A retrospective analysis of 119 patients, where all records including age, sex, treatment processes and costs were extracted from the patients’ profiles and examined. Results: The mean age of patients was 50.8 (±10.2) years. The total sample cost was Jordanian dinar 1,393,325 (US$1,963,560). The mean cost per patient from stage I to IV was Jordanian dinar 6696, 9183, 11,970 and 15,073, respectively. Medications were the most expensive resource used. Stage IV had the highest cost and largest number of patients. Conclusion: Direct medical costs associated with BC are considerable. Three-quarters of the cost were devoted to medications.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2019-0014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44799068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Diltiazem potentiation of doxorubicin cytotoxicity and cellular uptake in human breast cancer cells 地尔硫卓对人乳腺癌症细胞阿霉素细胞毒性和细胞摄取的增强作用
IF 0.7
Breast Cancer Management Pub Date : 2019-12-01 DOI: 10.2217/bmt-2019-0018
Hamdan S Al-malky, Z. A. Damanhouri, Jumana Y Al Aama, A. A. Al Qahtani, W. Ramadan, H. Alkreathy, Sameer E Al Harthi, A. Osman
{"title":"Diltiazem potentiation of doxorubicin cytotoxicity and cellular uptake in human breast cancer cells","authors":"Hamdan S Al-malky, Z. A. Damanhouri, Jumana Y Al Aama, A. A. Al Qahtani, W. Ramadan, H. Alkreathy, Sameer E Al Harthi, A. Osman","doi":"10.2217/bmt-2019-0018","DOIUrl":"https://doi.org/10.2217/bmt-2019-0018","url":null,"abstract":"Aim: Breast cancer is the most common cancer among Arab women and also around the world. Chronic cardiotoxicity and multidrug resistance are potential limiting factors of doxorubicin (DOX), a known anthracycline antibiotic. Materials & methods: DOX cytotoxicity was evaluated by the sulforhodamine method. DOX cellular uptake, detection of P-glycoprotein activity and the photomicrograph of MCF-7 cells were also determined. Results: Diltiazem (DIL) treatment improved DOX cytotoxic activity and increased the cellular uptake of DOX significantly and aggregation of rhodamine 123, reflecting inhibition of P-glycoprotein pump. Cytopathological investigation of MCF-7 cells revealed marked cytotoxic activity of DOX in the presence of DIL. Conclusion: DIL treatment enhanced DOX cytotoxic effect and reduced multidrug resistance, which increased the drug accumulation intracellularly.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2019-0018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48372293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Male breast cancer: a neglected disease 男性乳腺癌:一种被忽视的疾病
IF 0.7
Breast Cancer Management Pub Date : 2019-12-01 DOI: 10.2217/bmt-2019-0020
I. Fentiman
{"title":"Male breast cancer: a neglected disease","authors":"I. Fentiman","doi":"10.2217/bmt-2019-0020","DOIUrl":"https://doi.org/10.2217/bmt-2019-0020","url":null,"abstract":"Male breast cancer (MBC) is rare, tending to afflict sedentary men, with adolescent obesity being a risk factor. Men fare worse compared with matched females with breast cancer. The preponderance of ER+ve disease affects the molecular profile: most cases have luminal A tumors. Through male ignorance and risk-taking, delay is frequent and this lacuna needs addressing with health education. The major gene mutation responsible for MBC is BRCA2. Five single nucleotide polymorphisms (SNPs) are significantly and uniquely associated with MBC risk with two located in the 8q24.21 regions. Mastectomy is being gradually replaced by nipple-preserving surgery and radiotherapy but this trend could be expedited with neoadjuvant endocrine therapy. Significant advances will occur only after expansion of collaborative groups and this is a matter of pressing importance.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":"8 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2019-0020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43696735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Accuracy among Jordanian and Australian radiologists reading the same set of test screening cases 约旦和澳大利亚放射科医生阅读同一组测试筛选病例的准确性
IF 0.7
Breast Cancer Management Pub Date : 2019-11-01 DOI: 10.2217/bmt-2018-0021
M. Rawashdeh, M. Abdelrahman, M. Zaitoun, M. Suleiman, Rula Abu Taimai, T. Nusairat, P. Brennan
{"title":"Accuracy among Jordanian and Australian radiologists reading the same set of test screening cases","authors":"M. Rawashdeh, M. Abdelrahman, M. Zaitoun, M. Suleiman, Rula Abu Taimai, T. Nusairat, P. Brennan","doi":"10.2217/bmt-2018-0021","DOIUrl":"https://doi.org/10.2217/bmt-2018-0021","url":null,"abstract":"Aim: To investigate how breast radiologists from Jordan and Australia differ in accuracy when examining the set of test screening cases. Materials & methods: A total of 27 Jordanian and 115 Australian breast radiologists were requested to read 60 mammographic images and to indicate the location of any perceived lesion and record a confidence level ranging from 1 to 5. Jackknife alternative free-response receiver operating characteristic, location sensitivity and specificity were calculated and compared for both Australian and Jordanian readers. Results: Australian readers achieved significantly higher readings accuracy than Jordanian readers retrospectively in terms of Jackknife alternative free-response receiver operating characteristic (75th percentile values: 0.863 vs 0.600; p = 0.001) and location sensitivity (75th percentile values 0.673 vs 0.571; p = 0.022). Conclusion: Australian radiologists achieved higher performance in reading breast mammograms than Jordanian radiologists.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2018-0021","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43552471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metronomic capecitabine with aromatase inhibitors for patients with metastatic hormone-receptor positive, HER2-negative breast cancer 计量卡培他滨联合芳香化酶抑制剂治疗转移性激素受体阳性、HER2阴性乳腺癌症患者
IF 0.7
Breast Cancer Management Pub Date : 2019-11-01 DOI: 10.2217/bmt-2019-0012
Bader A Abdelmaksoud, Mostafa Toam, A. Fayed
{"title":"Metronomic capecitabine with aromatase inhibitors for patients with metastatic hormone-receptor positive, HER2-negative breast cancer","authors":"Bader A Abdelmaksoud, Mostafa Toam, A. Fayed","doi":"10.2217/bmt-2019-0012","DOIUrl":"https://doi.org/10.2217/bmt-2019-0012","url":null,"abstract":"Aim: To evaluate the efficacy and safety of combined metronomic capecitabine with aromatase inhibitors (AIs) for patients with newly diagnosed metastatic hormone-receptor positive, HER2-negative breast cancer. Patients & methods: A total of 41 women with a diagnosis of metastatic hormone-receptor positive, HER2-negative breast cancer received oral metronomic capecitabine, 500 mg/m2 twice daily combined with an AI. Results: After a median follow-up of 24 months (9–50), a median of 15 months of treatment were completed, the median time to progression was 15 months (12.6–17.3) and the median overall survival was 37 months (23.6–50.4). The treatment was tolerated with less than 10% grade 3 toxicities. Conclusion: Combination of metronomic capecitabine and AIs appears to be safe and has encouraging results in advanced hormone-receptor positive, HER2-negative breast cancer.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.7,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2019-0012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46208362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信